BridgeBio Pharma
BBIO
BBIO
95 hedge funds and large institutions have $3.28B invested in BridgeBio Pharma in 2020 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 16 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
4.52% more ownership
Funds ownership: 86.77% → 91.29% (+4.5%)
11% less capital invested
Capital invested by funds: $3.67B → $3.28B (-$389M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Holders
95
Holding in Top 10
6
Calls
$11.3M
Puts
$3.19M
Top Buyers
| 1 | +$74.3M | |
| 2 | +$26.3M | |
| 3 | +$13.7M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$12.7M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.9M |
Top Sellers
| 1 | -$39.3M | |
| 2 | -$23.9M | |
| 3 | -$16.4M | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
-$4.28M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.75M |